iBio (IBIO) Total Non-Current Liabilities (2022 - 2023)

iBio's (IBIO) quarterly Total Non-Current Liabilities came in at $24.2 million in Q3 2023, down 4.32% on a QoQ basis from $25.3 million in Q2 2023.

iBio (IBIO) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends

iBio (IBIO) has 2 years of Total Non-Current Liabilities data on file, last reported at $24.2 million in Q3 2023.

On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $24.2 million in Q3 2023; TTM through Sep 2023 was $24.2 million, a N/A change from a year earlier, with the FY2023 full-year figure at $25.3 million, changed N/A from the prior year.
Total Non-Current Liabilities for Q3 2023 stood at $24.2 million, down from $25.3 million in the prior quarter.
Over the last five years, Total Non-Current Liabilities for IBIO reached as high as $31.9 million in Q4 2022 and fell as low as $24.2 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	4.45 Mn
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	110.28 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	19.49 Mn
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	1.98 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	5.87 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	7.32 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	40.00 Mn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	746.94 Mn
10	iBio	172.22 Mn	172.22 Mn	-	-

Download Data